Becton, Dickinson and Company (LON:0R19)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 38.37B -9.5% |
| Revenue (ttm) | 16.95B +18.5% |
| Net Income | 709.99M -40.6% |
| EPS | 2.51 -39.2% |
| Shares Out | n/a |
| PE Ratio | 54.04 |
| Forward PE | 14.40 |
| Dividend | 3.16 (2.26%) |
| Ex-Dividend Date | Sep 9, 2026 |
| Volume | 108 |
| Open | 189.10 |
| Previous Close | 188.18 |
| Day's Range | 186.71 - 191.77 |
| 52-Week Range | 139.58 - 212.51 |
| Beta | 0.26 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About LON:0R19
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, va... [Read more]
Financial Performance
In fiscal year 2025, LON:0R19's revenue was $21.84 billion, an increase of 8.24% compared to the previous year's $20.18 billion. Earnings were $1.68 billion, a decrease of -1.58%.
Financial numbers in USD Financial StatementsNews
BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
FRANKLIN LAKES, N.J., Aug. 17, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named execut...
BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
Enrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgery FRANKLIN LAKES, N.J., Aug....
Becton, Dickinson and Company Earnings Call Transcript: Q3 2026
Q3 delivered strong revenue and EPS growth, driven by double-digit gains in key platforms and robust U.S. performance, offset by Alaris and China vaccine headwinds. FY26 guidance was raised, with continued focus on innovation, operational excellence, and capital returns.
Becton, Dickinson and Company Slides: Q3 2026
Becton, Dickinson and Company has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on August 6, 2026.
Becton, Dickinson and Company Earnings release: Q3 2026
Becton, Dickinson and Company released its Q3 2026 earnings on August 6, 2026, summarizing the period's financial results.
Becton, Dickinson and Company Quarterly report: Q3 2026
Becton, Dickinson and Company has published its Q3 2026 quarterly earnings report on August 6, 2026.
BD Reports Third Quarter Fiscal 2026 Financial Results
Revenue of $5.0 billion increased 5.4% as reported, 4.4% FXN GAAP and adjusted diluted EPS from continuing operations of $1.64 and $3.23, respectively Year-to-date cash from continuing operations incr...
Becton Dickinson issues recall on certain lots of needle sets used for emergency IV access
Becton Dickinson said on Friday it is issuing a recall on certain lots of medical needle sets in the U.S. after users reported difficulty in removing a part of the device after using it on patients.
EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch
Collaboration pairs leadership in pharmaceuticals and advanced drug delivery technology to support a consistent, reliable treatment experience for metabolic disease patients. FRANKLIN LAKES, N.J.
BD Board Declares Dividend
FRANKLIN LAKES, N.J., July 28, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declar...
Mike Garrison to Retire from BD
FRANKLIN LAKES, N.J., July 22, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Michael (Mike) Garrison has in...
BD to Announce Financial Results for its Third Quarter of Fiscal 2026
FRANKLIN LAKES, N.J., July 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio we...
BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System
Recognition from Vizient validates CentroVena One™ as a breakthrough innovation designed to simplify central line insertion and enhance patient and clinician safety FRANKLIN LAKES, N.J., June 23, 2026...
BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
New laser system is designed to help urology teams enhance efficiency, versatility, and procedural workflow across stone management and soft tissue procedures. FRANKLIN LAKES, N.J.
These 5 Stocks Have 50 Years of Dividend Growth—Here's How to Find More
With a new presidential administration set to take office on Jan. 20, 2025, some investors may be uncertain about how new policies and personnel will affect the stock market and interest rates. Will t...
Peter Menziuso Named EVP and President, BD Interventional
FRANKLIN LAKES, N.J., May 18, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Peter Menziuso has been named execu...
AI, Robotics Key to Transforming Health Care: BD CEO
Tom Polen, CEO of medical technology company BD, says that in the next decade AI and robotics will transform health care in ways that will make today's system seem archaic. Polen sits down with Bloomb...
Becton, Dickinson and Company Transcript: Bank of America Global Healthcare Conference 2026
Leadership is focused on transparency, capital allocation, and operational rigor to drive growth, with 30% of the portfolio growing double digits and ongoing investments in high-margin areas. Headwinds from Alaris, vaccines, and China are being managed, while margin expansion is supported by productivity and cost controls.
Becton, Dickinson and Company Earnings Call Transcript: Q2 2026
Q2 revenue rose 2.6% to $4.7B, with strong growth in key platforms and adjusted EPS of $2.90. Full-year adjusted EPS guidance was raised to $12.52–$12.72, reflecting broad-based execution and improved outlook. Share repurchases and innovation remain capital priorities.
Becton, Dickinson and Company Slides: Q2 2026
Becton, Dickinson and Company has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 7, 2026.
Becton, Dickinson and Company Earnings release: Q2 2026
Becton, Dickinson and Company released its Q2 2026 earnings on May 7, 2026, summarizing the period's financial results.
Becton, Dickinson and Company Quarterly report: Q2 2026
Becton, Dickinson and Company has published its Q2 2026 quarterly earnings report on May 7, 2026.
Becton Dickinson raises annual profit forecast on strength in drug delivery devices
Becton Dickinson raised its annual profit forecast on Thursday, riding strong demand for its drug-delivery devices and surgical equipment, and appointed Vitor Roque as its chief financial officer.
BD Appoints Vitor Roque Chief Financial Officer
FRANKLIN LAKES, N.J., May 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Vitor Roque has been named executive...